123 related articles for article (PubMed ID: 12967930)
1. Tyr-c[D-Orn-Tyr(Bzl)-Pro-Gly]: a novel antiproliferative acting somatostatin receptor agonist with mu-opioid receptor-sensitizing properties.
Stirnweiss J; Hartrodt B; Greksch G; Stürzebecher U; Böhmer FD; Neubert K; Liebmann C
Br J Pharmacol; 2003 Sep; 140(1):13-22. PubMed ID: 12967930
[TBL] [Abstract][Full Text] [Related]
2. Effect of aromatic amino acid substitutions in the 3-position of cyclic beta-casomorphin analogues on mu-opioid agonist/delta-opioid antagonist properties.
Schmidt R; Wilkes BC; Chung NN; Lemieux C; Schiller PW
Int J Pept Protein Res; 1996 Nov; 48(5):411-9. PubMed ID: 8956074
[TBL] [Abstract][Full Text] [Related]
3. Somatostatin and its receptor family.
Patel YC
Front Neuroendocrinol; 1999 Jul; 20(3):157-98. PubMed ID: 10433861
[TBL] [Abstract][Full Text] [Related]
4. Differential regulation of mu and delta opiate receptors by morphine, selective agonists and antagonists and differentiating agents in SH-SY5Y human neuroblastoma cells.
Zadina JE; Harrison LM; Ge LJ; Kastin AJ; Chang SL
J Pharmacol Exp Ther; 1994 Sep; 270(3):1086-96. PubMed ID: 7932156
[TBL] [Abstract][Full Text] [Related]
5. Somatostatin receptors 1 and 5 heterodimerize with epidermal growth factor receptor: agonist-dependent modulation of the downstream MAPK signalling pathway in breast cancer cells.
Watt HL; Kharmate GD; Kumar U
Cell Signal; 2009 Mar; 21(3):428-39. PubMed ID: 19070659
[TBL] [Abstract][Full Text] [Related]
6. Novel peptidic mu opioid antagonists: pharmacologic characterization in vitro and in vivo.
Kramer TH; Shook JE; Kazmierski W; Ayres EA; Wire WS; Hruby VJ; Burks TF
J Pharmacol Exp Ther; 1989 May; 249(2):544-51. PubMed ID: 2566679
[TBL] [Abstract][Full Text] [Related]
7. Delta opioid receptor enhancement of mu opioid receptor-induced antinociception in spinal cord.
He L; Lee NM
J Pharmacol Exp Ther; 1998 Jun; 285(3):1181-6. PubMed ID: 9618421
[TBL] [Abstract][Full Text] [Related]
8. Effects of systemic administration of beta-casomorphin-5 on learning and memory in mice.
Sakaguchi M; Koseki M; Wakamatsu M; Matsumura E
Eur J Pharmacol; 2006 Jan; 530(1-2):81-7. PubMed ID: 16360145
[TBL] [Abstract][Full Text] [Related]
9. Effects of naloxone and D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 and the protein kinase inhibitors H7 and H8 on acute morphine dependence and antinociceptive tolerance in mice.
Bilsky EJ; Bernstein RN; Wang Z; Sadée W; Porreca F
J Pharmacol Exp Ther; 1996 Apr; 277(1):484-90. PubMed ID: 8613958
[TBL] [Abstract][Full Text] [Related]
10. Potency differences for D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 as an antagonist of peptide and alkaloid micro-agonists in an antinociception assay.
Sterious SN; Walker EA
J Pharmacol Exp Ther; 2003 Jan; 304(1):301-9. PubMed ID: 12490605
[TBL] [Abstract][Full Text] [Related]
11. Intact cell binding and the relation to opioid activities in SH-SY5Y cells.
Toll L
J Pharmacol Exp Ther; 1995 May; 273(2):721-7. PubMed ID: 7752076
[TBL] [Abstract][Full Text] [Related]
12. Interactions among mu- and delta-opioid receptors, especially putative delta1- and delta2-opioid receptors, promote dopamine release in the nucleus accumbens.
Hirose N; Murakawa K; Takada K; Oi Y; Suzuki T; Nagase H; Cools AR; Koshikawa N
Neuroscience; 2005; 135(1):213-25. PubMed ID: 16111831
[TBL] [Abstract][Full Text] [Related]
13. Interaction of cholecystokinin and somatostatin with a selective mu-opioid agonist and mu- and kappa-antagonists in thermoregulation.
Ghosh S; Geller EB; Adler MW
Brain Res; 1997 Jan; 745(1-2):152-7. PubMed ID: 9037404
[TBL] [Abstract][Full Text] [Related]
14. Comparative pharmacological properties and functional coupling of mu and delta opioid receptor sites in human neuroblastoma SH-SY5Y cells.
Kazmi SM; Mishra RK
Mol Pharmacol; 1987 Jul; 32(1):109-18. PubMed ID: 3037297
[TBL] [Abstract][Full Text] [Related]
15. Agonist-induced functional desensitization of the mu-opioid receptor is mediated by loss of membrane receptors rather than uncoupling from G protein.
Pak Y; Kouvelas A; Scheideler MA; Rasmussen J; O'Dowd BF; George SR
Mol Pharmacol; 1996 Nov; 50(5):1214-22. PubMed ID: 8913353
[TBL] [Abstract][Full Text] [Related]
16. Mu-opioid receptor-mediated phosphorylation of IkappaB kinase in human neuroblastoma SH-SY5Y cells.
Liu AM; Wong YH
Neurosignals; 2005; 14(3):136-42. PubMed ID: 16088228
[TBL] [Abstract][Full Text] [Related]
17. Mu opiate receptor down-regulation by morphine and up-regulation by naloxone in SH-SY5Y human neuroblastoma cells.
Zadina JE; Chang SL; Ge LJ; Kastin AJ
J Pharmacol Exp Ther; 1993 Apr; 265(1):254-62. PubMed ID: 8097244
[TBL] [Abstract][Full Text] [Related]
18. Differential coupling of mu-, delta-, and kappa-opioid receptors to G alpha16-mediated stimulation of phospholipase C.
Lee JW; Joshi S; Chan JS; Wong YH
J Neurochem; 1998 May; 70(5):2203-11. PubMed ID: 9572309
[TBL] [Abstract][Full Text] [Related]
19. Novel diastereomeric opioid tetrapeptides exhibit differing pharmacological activity profiles.
Ioja E; Tourwé D; Kertész I; Tóth G; Borsodi A; Benyhe S
Brain Res Bull; 2007 Sep; 74(1-3):119-29. PubMed ID: 17683797
[TBL] [Abstract][Full Text] [Related]
20. Morphiceptin and beta-casomorphin-5 analogues containing a reduced peptide bond: selective mu-receptor agonists and a novel mu antagonist, H-Tyr-Pro psi (CH2-NH)Phe-Pro-Gly-OH.
Delaet NG; Verheyden PM; Tourwe D; Van Binst G; Davis P; Burks TF
Biopolymers; 1992 Aug; 32(8):957-69. PubMed ID: 1330047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
